ELAN
Price
$23.17
Change
-$0.73 (-3.05%)
Updated
Jun 23, 04:59 PM (EDT)
Capitalization
11.94B
48 days until earnings call
Intraday BUY SELL Signals
EVO
Price
$2.65
Change
+$0.02 (+0.76%)
Updated
Jun 23, 03:40 PM (EDT)
Capitalization
942.51M
51 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ELAN vs EVO

ELAN vs EVO Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ELAN vs. EVO commentary
Jun 24, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELAN is a Hold and EVO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 24, 2026
Stock price -- (ELAN: $23.90 vs. EVO: $2.62)
Brand notoriety: ELAN: Notable vs. EVO: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ELAN: 83% vs. EVO: 58%
Market capitalization -- ELAN: $11.94B vs. EVO: $942.51M
ELAN [@Pharmaceuticals: Generic] is valued at $11.94B. EVO’s [@Pharmaceuticals: Generic] market capitalization is $942.51M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ELAN’s FA Score shows that 1 FA rating(s) are green whileEVO’s FA Score has 1 green FA rating(s).

  • ELAN’s FA Score: 1 green, 4 red.
  • EVO’s FA Score: 1 green, 4 red.
According to our system of comparison, ELAN is a better buy in the long-term than EVO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ELAN’s TA Score shows that 5 TA indicator(s) are bullish while EVO’s TA Score has 3 bullish TA indicator(s).

  • ELAN’s TA Score: 5 bullish, 2 bearish.
  • EVO’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, ELAN is a better buy in the short-term than EVO.

Price Growth

ELAN (@Pharmaceuticals: Generic) experienced а -1.61% price change this week, while EVO (@Pharmaceuticals: Generic) price change was -6.43% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.70%. For the same industry, the average monthly price growth was +0.08%, and the average quarterly price growth was +8.31%.

Reported Earning Dates

ELAN is expected to report earnings on Aug 10, 2026.

EVO is expected to report earnings on Aug 13, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.70% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ELAN($11.9B) has a higher market cap than EVO($943M). ELAN YTD gains are higher at: 5.612 vs. EVO (-14.935). ELAN has higher annual earnings (EBITDA): 731M vs. EVO (-164.48M). EVO has more cash in the bank: 464M vs. ELAN (428M). EVO has less debt than ELAN: EVO (387M) vs ELAN (3.99B). ELAN has higher revenues than EVO: ELAN (4.89B) vs EVO (745M).
ELANEVOELAN / EVO
Capitalization11.9B943M1,262%
EBITDA731M-164.48M-444%
Gain YTD5.612-14.935-38%
P/E Ratio374.14N/A-
Revenue4.89B745M657%
Total Cash428M464M92%
Total Debt3.99B387M1,031%
FUNDAMENTALS RATINGS
ELAN vs EVO: Fundamental Ratings
ELAN
EVO
OUTLOOK RATING
1..100
2765
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
91
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9397
PRICE GROWTH RATING
1..100
4262
P/E GROWTH RATING
1..100
12
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EVO's Valuation (91) in the null industry is in the same range as ELAN (92) in the Agricultural Commodities Or Milling industry. This means that EVO’s stock grew similarly to ELAN’s over the last 12 months.

EVO's Profit vs Risk Rating (100) in the null industry is in the same range as ELAN (100) in the Agricultural Commodities Or Milling industry. This means that EVO’s stock grew similarly to ELAN’s over the last 12 months.

ELAN's SMR Rating (93) in the Agricultural Commodities Or Milling industry is in the same range as EVO (97) in the null industry. This means that ELAN’s stock grew similarly to EVO’s over the last 12 months.

ELAN's Price Growth Rating (42) in the Agricultural Commodities Or Milling industry is in the same range as EVO (62) in the null industry. This means that ELAN’s stock grew similarly to EVO’s over the last 12 months.

ELAN's P/E Growth Rating (1) in the Agricultural Commodities Or Milling industry is in the same range as EVO (2) in the null industry. This means that ELAN’s stock grew similarly to EVO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ELANEVO
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
60%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
Bullish Trend 2 days ago
61%
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
71%
Bearish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 9 days ago
66%
Bullish Trend 23 days ago
68%
Declines
ODDS (%)
Bearish Trend 7 days ago
75%
Bearish Trend 6 days ago
79%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
65%
View a ticker or compare two or three
Interact to see
Advertisement
ELAN
Daily Signal:
Gain/Loss:
EVO
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RGNX9.061.26
+16.22%
REGENXBIO
HTO56.64-0.05
-0.09%
H2O America
ALGN173.76-8.32
-4.57%
Align Technology
KIDZ1.42-0.07
-4.70%
KIDZ AI Inc
GEG2.38-0.38
-13.77%
Great Elm Group

EVO and

Correlation & Price change

A.I.dvisor indicates that over the last year, EVO has been loosely correlated with SNDL. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if EVO jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EVO
1D Price
Change %
EVO100%
+2.34%
SNDL - EVO
42%
Loosely correlated
-1.06%
PRGO - EVO
40%
Loosely correlated
-6.34%
ACET - EVO
26%
Poorly correlated
+1.60%
ELAN - EVO
25%
Poorly correlated
-1.32%
AMPH - EVO
23%
Poorly correlated
-2.60%
More